The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.

Phase 3

• Conditions: Nosocomial Infection
• Interventions: Drug: Garlic powder standardized to allicin

• Registration Number: NCT06833125
• Lead Sponsor: Alexandria University

Brief Summary

The goal of this clinical trial is to learn if garlic tablets works to prevent nosocomial infections in hospitalized patients in ICU. The main questions it aims to answer are:

Does garlic tablets administration lower the occurence of nosocomial infections in hospitalized patients in ICU?

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-12
• Study First Submitted QC: 2025-02-15
• Study First Posted: 2025-02-18
• Study Start: 2025-03-01
• Last Update Submitted: 2025-10-02
• Last Update Posted: 2025-10-07
• Primary Completion: 2026-03-01
• Study Completion: 2026-04-01

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• All patients aged from 18 to 65 years old admitted to intensive care units without any type of infection.

Exclusion Criteria

1. Patients with signs /symptoms of infection.
2. Patients with human immunodeficiency virus, malignancy and patients with a history of recent immunosuppressants or corticosteroids administration.
3. Patients with bleeding disorders or abnormal coagulation profile
4. Patients who will planned for surgery within 2 weeks.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
The intervention group	Garlic powder standardized to allicin	The patients in the intervention group which will receive garlic tablets (Tomex plus 300 mg) two tablets twice daily for 6 days just after ICU admission

Primary Outcome Measures

Name	Time	Method
Occurrence of central line-associated bloodstream infections, catheter- associated urinary tract infections, surgical site infections and ventilator- associated pneumonia in the two groups (by cultures results).	one year

Secondary Outcome Measures

Name	Time	Method
Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups .	one year	The Mean of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups will be calculated.

Trial Locations

Locations (1)

Alexandria Main University Hospital; 🇪🇬 Alexandria, Alexandria Governorate, Egypt